Noyada Solution (Oral)

Captopril

1mg/ml

MARTINDALE PHARMACEUTICALS

Pack size	100ml Amber Glass Bottle
Dispensing mode	POM
Source	UK
Agent	METROPOLITAN MEDICAL MARKETING
Retail Price	414.00 AED

Available as:

5mg/ml - Solution (Oral)

Indications

Noyada Solution (Oral) is used for: Hypertension, Congestive heart failure, Post Myocardial infarction, Diabetic nephropathy

Adult Dose

Adult: PO HTN Initial: 12.5 mg twice daily. Maintenance: 25-50 mg twice daily. Max: 50 mg 3 times/day. Elderly: Initially, 6.25 mg bid. Heart failure Initial: 6.25-12.5 mg 2-3 times/day. Max: 50 mg 3 times/day. Post MI Start 3 days after MI. Initial: 6.25 mg/day, may increase after several wk to 150 mg/day in divided doses if needed and tolerated. Diabetic nephropathy 25 mg 3 times/day.

Child Dose

Oral Hypertension Child: Neonates and infants: 0.15 mg/kg. Max: 6 mg/kg in 2 or 3 divided doses according to response. Childn and adolescents: 0.3 mg/kg. Max: 6 mg/kg in 2 or 3 divided doses according to response. Heart failure Child: Initially, 0.25 mg/kg/day, increased up to 2.5 or 3.5 mg/kg/day in 3 divided doses.

Renal Dose

Renal impairment: CrCl (ml/min) <10 Initially, 6.25 mg/day. Max: 37.5 mg/day. 10-20 Initially, 12.5 mg/day. Max: 75 mg/day. 21-40 Initially, 25 mg/day. Max: 100 mg/day.

Administration

Should be taken on an empty stomach. Take on an empty stomach 1 hr before or 2 hr after meals.

Contra Indications

Known hypersensitivity to the drug. Bilateral renal artery stenosis, hereditary angioedema; renal impairment; pregnancy.

Precautions

Patients on diuretics or with sodium depletion should discontinue diuretics or increase sodium intake prior to initiation of therapy. Renal impairment, SLE and other autoimmune collagen disorders and during concurrent use of immunosuppressant or leucopenic drugs, monitor WBC count and urinary protein before and during therapy. Lactation. Porphyria. Severe CHF. Discontinue as soon as pregnancy detected; during the second and third trimesters of pregnancy, drugs that act directly on the renin-angiotensin have been associated with fetal injury that includes hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death Lactation: enters breast milk/not recommended (AAP states compatible with nursing)

Pregnancy-Lactation

Pregnancy Category: C; D in 2nd & 3rd trimesters Discontinue as soon as pregnancy detected; during the second and third trimesters of pregnancy, drugs that act directly on the renin-angiotensin have been associated with fetal injury that includes hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death Lactation: enters breast milk/not recommended (AAP states compatible with nursing)

Interactions

Concurrent treatment w/ NSAIDs reduces hypotensive action and increases the risk of nephrotoxicity. Additive hyperkalaemic effect w/ K supplements, K-sparing diuretics, and other drugs (e.g. heparin). May increase risk of leucopenia w/ procainamide, allopurinol, cytostatic or immunosuppressants. May increase risk of lithium toxicity. Increased risk of nitritoid reactions w/ gold (Na aurothiomalate). Potentially Fatal: Increased risk of hypotension, hyperkalaemia, and changes in renal function (including acute renal failure) w/ aliskiren in diabetic patients.

Adverse Effects

Side effects of Captopril : >10% Hyperkalemia (1-11%) 1-10% Hypersensitivity rxns (4-7%), Skin rash (4-7%), Dysgeusia (2-4%), Hypotension (1-2.5%), Pruritus (2%), Cough (0.5-2%), Chest pain (1%), Palpitations (1%), Proteinuria (1%), Tachycardia (1%) Frequency Not Defined Cardiac arrest, Orthostatic hypotension, Ataxia, Confusion, Depression, Somnolence, Angioedema, Photosensitivity, Neutropenia, ARF if renal artery stenosis, Renal impairment, Impotence Potentially Fatal: Neutropenia, usually occurs within 3 mth of starting therapy especially in patients with renal dysfunction or collagen diseases. Hyperkalaemia. Anaphylactic reactions.

Mechanism of Action

Captopril competitively inhibits the conversion of angiotensin I (ATI) to angiotensin II (ATII), thus resulting in reduced ATII levels and aldosterone secretion. It also increases plasma renin activity and bradykinin levels. Reduction of ATII leads to decreased Na and water retention. This promotes vasodilation and BP reduction.

Note

Noyada 1mg/ml Solution (Oral) manufactured by MARTINDALE PHARMACEUTICALS. Its generic name is Captopril. Noyada is availble in United Arab Emirates. Farmaco UAE drug index information on Noyada Solution (Oral) is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Captopril :

Tablets

Midopril ^25mg

MID PHARMA - MIDDLE EAST PHARMACEUTICAL AND CHEMICAL INDUSTRIES AND MEDICAL APPLIANCES CO.

Tablets

Midopril ^50mg

MID PHARMA - MIDDLE EAST PHARMACEUTICAL AND CHEMICAL INDUSTRIES AND MEDICAL APPLIANCES CO.